Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Summary
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
Official title: Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With High-risk, Refractory or Relapsed AML
Key Details
Gender
All
Age Range
6 Months - 30 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2021-11-01
Completion Date
2026-06
Last Updated
2024-08-28
Healthy Volunteers
No
Conditions
Interventions
NK cell infusions
Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
Locations (1)
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk, Minsk Oblast, Belarus